Seller record · Telehealth service

Curex

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The weight loss page refers only to a licensed US compounding pharmacy, and the terms to a network of partner pharmacies. 1 more criterion also fails; see the table below.

At a glance

CurexTelehealth service

6/8criteria passed

Price: Plans from $199 a month
Sells: compounded semaglutide injection, compounded semaglutide oral tablet, and 2 more
FDA letters: 1 on file

Visit Curex See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

An online allergy clinic that also runs a GLP-1 weight loss program selling compounded semaglutide and tirzepatide as weekly injections or daily tablets, with prescribing by a licensed physician or nurse practitioner after an online questionnaire. No pharmacy is named.

Operating entity Curex, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Curex's GLP page; Curex's terms of use page
S2	Prescription gating	PASS	Curex's GLP page
S3	Pharmacy identification	FAIL	Curex's GLP page; Curex's terms of use page
S4	Compounding disclosure	PASS	Curex's GLP page; Curex's terms of use page
S5	Analytical documentation	FAIL	Curex's GLP page
S6	Business address	PASS	Curex's website; Curex's terms of use page; Curex's privacy policy
S7	Price disclosure	PASS	Curex's GLP page
S8	Enforcement status	PASS	FDA's website; FDA warning letter 716821

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSEvery treatment plan is written by a licensed US physician or nurse practitioner who reviews the buyer's full history before prescribing, and the terms name the Curex medical group practices that provide the care.Source: Curex's GLP page; Curex's terms of use page.

S2PASSThe weight loss page puts a questionnaire on medical history, goals and current medications first, then a licensed provider's review, then shipment, and promises a full refund if the buyer is not prescribed. No page describes a payment step before the questionnaire.Source: Curex's GLP page.

S3FAILNo filling pharmacy is named. The weight loss page refers only to a licensed US compounding pharmacy, and the terms to a network of partner pharmacies.Source: Curex's GLP page; Curex's terms of use page.

S4PASSThe weight loss page and the footer of the weight loss legal pages state that compounded medications have not been approved by the FDA and that the FDA has not evaluated their safety or efficacy.Source: Curex's GLP page; Curex's terms of use page.

S5FAILThe weight loss page says every batch is third-party tested for potency, sterility, pH and endotoxins and that lab results are available on request, but no certificate of analysis or lot document is published.Source: Curex's GLP page.

S6PASSCurex, Inc. at 777 Brickell Ave #500-95053, Miami, FL 33131, printed in the footer of every page and in the terms, the privacy policy and the telehealth consent. The terms name Delaware law.Source: Curex's website; Curex's terms of use page; Curex's privacy policy.

S7PASSThe weight loss page gives $199 a month as the starting price, with no membership fee, and runs a summer sale on the opening month: from $49 for semaglutide injections or tablets and from $149 for tirzepatide injections or tablets. It does not say what either medication costs after that month.Source: Curex's GLP page.

S8PASSFDA warning letter 716821, September 2025, names Curex at the Miami address the seller prints and reviewed the seller's own website. It alleges that claims of clinically proven weight loss and of the same active ingredients as Ozempic, Mounjaro and Zepbound are false or misleading for compounded semaglutide and tirzepatide. No close-out letter appears in the index. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 716821.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injection, compounded semaglutide oral tablet, compounded tirzepatide injection, compounded tirzepatide oral tablet.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 716821, issued September 2025, to CurexClaims on Curex's website that compounded semaglutide and tirzepatide have the same active ingredients as Ozempic, Mounjaro and Zepbound, and are clinically proven weight loss treatments, are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Curex

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.